The traditional pharmaceutical commercial model was built for a market that no longer exists. Greater scrutiny of value, more complex customer relationships, new channels of engagement, and mounting pressure on margins are forcing companies to reconsider how they organize, invest, and compete. Numerof’s 2026 Commercial Model Survey Report, based on input from 175 pharmaceutical executives, examines how commercial models are changing, what is driving those decisions, and where organizations are placing their bets for the future.

Numerof’s recently released Commercial Model Survey Report has attracted nationwide attention in multiple publications:

• BioSpace: Drugmakers cherry pick launch regions as MFN creates ‘policy environment like an earthquake’
• BioWorld: Rx companies rethinking commercialization in seismic shift
• Fierce Pharma: Drug pricing policy ‘earthquake’ forcing rethink of global commercialization plans: survey
• Pharmaceutical Commerce: Pharma Pulse: DHL’s New Singapore Hub and Pharma Rethinks Go-To Market [Podcast]
• Pharmaceutical Technology: Pharma’s R&D, commercial approach shifts amid global policy evolution

Download the report to get the latest insights.